BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Bartolini B, Lionetti R, Giombini E, Sias C, Taibi C, Montalbano M, D'Offizi G, McPhee F, Hughes EA, Zhou N, Ippolito G, Garbuglia AR, Capobianchi MR. Dynamics of HCV genotype 4 resistance-associated variants during virologic escape with pIFN/RBV+daclatasvir: a case study using ultra deep pyrosequencing. J Clin Virol 2015;66:38-43. [PMID: 25866334 DOI: 10.1016/j.jcv.2015.02.001] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
Number Citing Articles
1 Perpiñán E, Caro-Pérez N, García-González N, Gregori J, González P, Bartres C, Soria ME, Perales C, Lens S, Mariño Z, Londoño MC, Ariza X, Koutsoudakis G, Quer J, González-Candelas F, Forns X, Pérez-Del-Pulgar S. Hepatitis C virus early kinetics and resistance-associated substitution dynamics during antiviral therapy with direct-acting antivirals. J Viral Hepat 2018;25:1515-25. [PMID: 30141252 DOI: 10.1111/jvh.12986] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
2 Dustin LB, Bartolini B, Capobianchi MR, Pistello M. Hepatitis C virus: life cycle in cells, infection and host response, and analysis of molecular markers influencing the outcome of infection and response to therapy. Clin Microbiol Infect 2016;22:826-32. [PMID: 27592089 DOI: 10.1016/j.cmi.2016.08.025] [Cited by in Crossref: 41] [Cited by in F6Publishing: 33] [Article Influence: 6.8] [Reference Citation Analysis]
3 Zhou N, Han Z, Hartman-Neumann S, DeGray B, Ueland J, Vellucci V, Hernandez D, McPhee F. Characterization of NS5A polymorphisms and their impact on response rates in patients with HCV genotype 2 treated with daclatasvir-based regimens. J Antimicrob Chemother 2016;71:3495-505. [PMID: 27605597 DOI: 10.1093/jac/dkw336] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 2.5] [Reference Citation Analysis]
4 Huang SW, Hung SJ, Wang JR. Application of deep sequencing methods for inferring viral population diversity. J Virol Methods 2019;266:95-102. [PMID: 30690049 DOI: 10.1016/j.jviromet.2019.01.013] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
5 Colomba GME, Urone N, Marco VD, Ferraro D. Phylodynamic Analysis and Implication of HCV Genotype 4 Variability on Antiviral Drug Response and T-Cell Recognition. Viruses 2020;12:E1363. [PMID: 33260596 DOI: 10.3390/v12121363] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Gamal N, Gitto S, Andreone P. Efficacy and Safety of Daclatasvir in Hepatitis C: An Overview. J Clin Transl Hepatol 2016;4:336-44. [PMID: 28097103 DOI: 10.14218/JCTH.2016.00038] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
7 Srinivasu G, Kumar KN, Thirupathi C, Narayana CL, Murthy CP. Development and Validation of the Chiral HPLC Method for Daclatasvir in Gradient Elution Mode on Amylose-Based Immobilized Chiral Stationary Phase. Chromatographia 2016;79:1457-67. [DOI: 10.1007/s10337-016-3157-2] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 2.5] [Reference Citation Analysis]
8 Minosse C, Giombini E, Bartolini B, Capobianchi MR, Garbuglia AR. Ultra-Deep Sequencing Characterization of HCV Samples with Equivocal Typing Results Determined with a Commercial Assay. Int J Mol Sci 2016;17:E1679. [PMID: 27739414 DOI: 10.3390/ijms17101679] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
9 Palladino C, Ezeonwumelu IJ, Marcelino R, Briz V, Moranguinho I, Serejo F, Velosa JF, Marinho RT, Borrego P, Taveira N. Epidemic history of hepatitis C virus genotypes and subtypes in Portugal. Sci Rep. 2018;8:12266. [PMID: 30116054 DOI: 10.1038/s41598-018-30528-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
10 Perales C, Quer J, Gregori J, Esteban JI, Domingo E. Resistance of Hepatitis C Virus to Inhibitors: Complexity and Clinical Implications. Viruses. 2015;7:5746-5766. [PMID: 26561827 DOI: 10.3390/v7112902] [Cited by in Crossref: 35] [Cited by in F6Publishing: 30] [Article Influence: 5.0] [Reference Citation Analysis]
11 Fevery B, Verbinnen T, Peeters M, Janssen K, Witek J, Jessner W, De Meyer S, Lenz O. Virology analyses of HCV genotype 4 isolates from patients treated with simeprevir and peginterferon/ribavirin in the Phase III RESTORE study. J Viral Hepat 2017;24:28-36. [PMID: 27696653 DOI: 10.1111/jvh.12614] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]